Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Obstet Gynecol. Sep 8, 2026; 15(2): 120261
Published online Sep 8, 2026. doi: 10.5317/wjog.120261
Published online Sep 8, 2026. doi: 10.5317/wjog.120261
Sentinel lymph node biopsy in gynecologic cancers
Priyanka Singh, Department of Gynecological Oncology, Kalyan Singh Super Specialty Cancer Institute, Lucknow 226002, Uttar Pradesh, India
Author contributions: Singh P is the only author and has conceptualized, researched and drafted the manuscript from the studies published in PubMed.
Conflict-of-interest statement: There is no conflict of interest.
Corresponding author: Priyanka Singh, Additional Professor, Department of Gynecological Oncology, Kalyan Singh Super Specialty Cancer Institute, CG City Sultanpur Road, Lucknow 226002, Uttar Pradesh, India. drpriyankaci@gmail.com
Received: February 24, 2026
Revised: March 16, 2026
Accepted: April 14, 2026
Published online: September 8, 2026
Processing time: 192 Days and 21.5 Hours
Revised: March 16, 2026
Accepted: April 14, 2026
Published online: September 8, 2026
Processing time: 192 Days and 21.5 Hours
Core Tip
Core Tip: Sentinel lymph node (SLN) biopsy is redefining nodal staging in gynecologic oncology by reducing surgical morbidity without compromising oncologic outcomes. Evidence supports its use in early-stage cervical and endometrial cancers, with high diagnostic accuracy and survival equivalence to full lymphadenectomy in selected patients. However, technical variability, learning curves, and inconsistent global adoption remain barriers. As micrometastatic disease increasingly influences adjuvant treatment decisions, the challenge is no longer proof of concept, but whether health systems are ready to implement SLN biopsy as routine standard care.